Prevalence Study of the Etiology of Pregnancy Anemia

Prevalence Study of the Etiologies of Pregnancy Anemias

Status

UNKNOWN

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT03448432

Acronym

PREGAN

Enrollment

700

Registered

2018-02-28

Start date

2018-02-27

Completion date

2019-12-27

Last updated

2018-03-05

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Pregnancy Anemia

Keywords

Pregnancy Anemia

Brief summary

Anemia during pregnancy occurs in 41% of women. The most common etiology is iron deficiency, but studies to determine prevalence of other causes of anemia in pregnancy are still lacking. However, anemia in pregnancy lead to adverse pregnancy outcomes and increase risk of maternal and fœtal morbidity and mortality. Specific management of anemia is so needed.

Interventions

None listed

Study design

Observational model

COHORT

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

FEMALE

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* woman 18-years or older * woman with a normal pregnancy * anemia with accidental or symptomatic discovery, whatever the term of pregnancy * non opposition collected

Exclusion criteria

* Refuse to participate * Stopped pregnancy whatever the term * Medical abortion of pregnancy

Design outcomes

Primary

Measure	Time frame	Description
Prevalence of the etiologies of anemias occured during pregnancy	from date of inclusion until 6 weeks after delivery	Anemia in pregnancy is defined as hemoglobin level (Hb) \< 11 g/dL in the first and the third trimesters, and Hb \< 10.5 g/dL in the second trimester.

Secondary

Measure	Time frame	Description
Study of obstetrical complications in women with anemia	from date of inclusion until delivery	* Measure of the incidence of postpartum haemorrhage, instrumental extractions, caesareans sections, premature delivery, intra-uterine growth restriction or small for gestational age, placenta abruption, preeclampsia and low birth-weight newborn (\<3rd and \<10th percentile under neonatal morphometry curves) * Level of release, * 1-, 3- and 5-minutes Apgar score, * Arterial ans venous cord potential hydrogen (pH)
Study of the evolution of anemia during pregnancy and postpartum	from date of inclusion until 6 weeks after delivery	Measure of the Hb level monthly and at 6 weeks after delivery
Describe the etiological and therapeutic management of pregnancy anemias	from date of inclusion until 6 weeks after delivery	therapeutic management : etiologic treatment (supplemental iron, vitaminic replacement, others) and symptomatic treatment (numbers and rhythm of transfusions)

Countries

France

Contacts

Primary ContactMarie-Anne Couturier

marie-anne.couturier@chu-brest.fr0298223421

Outcome results